Ken-Ichi Harada (Kenichi Harada)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Combination Therapy

Radical Prostatectomy

Editorial Comment

Epidermal Growth Factor Receptor

Top Venues

International journal of urology : official journal of the Japanese Urological Association

Investigative and clinical urology

This page only lists publications with an associated author ORCID identifier.

Publications

Takuto Hara, Yuto Matsushita, Ken-Ichi Harada, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. International journal of urology : official journal of the Japanese Urological Association (2024)
Takuto Hara, Yuto Matsushita, Ken-Ichi Harada, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. International journal of urology : official journal of the Japanese Urological Association 31 (6) (2024)
Takuto Hara, Yuto Matsushita, Ken-Ichi Harada, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. International journal of urology : official journal of the Japanese Urological Association 31 (6) (2024)
Takuto Hara, Yuto Matsushita, Ken-Ichi Harada, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan. International journal of urology : official journal of the Japanese Urological Association 31 (6) (2024)
Takuto Hara, Junya Furukawa, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association (2023)
Ken-Ichi Harada, Hideaki Miyake, Junya Furukawa, Naohiro Fujimoto, Masato Fujisawa
Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association (2023)
Takuto Hara, Junya Furukawa, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Ken-Ichi Harada, Satoru Takahashi, Yuzo Nakano, Masato Fujisawa
The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion. International journal of urology : official journal of the Japanese Urological Association (2023)
Ken-Ichi Harada, Ryo Sato, Yukari Bando, Asuka Sano, Yuto Matsushita, Keita Tamura, Tomoaki Terakawa, Junya Furukawa, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan. International journal of urology : official journal of the Japanese Urological Association (2023)
Nishimoto Koshiro, Kenichi Nakajima, Masafumi Oyama, Go Kaneko, Satoru Takahashi, Hideyasu Matsuyama, Hiroaki Shiina, Tomohiko Ichikawa, Hiroyuki Horikoshi, Katsuyoshi Hashine, Yutaka Sugiyama, Takeshi Miyao, Manabu Kamiyama, Ken-Ichi Harada, Akito Ito, Atsushi Mizokami, null null
Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer. International journal of urology : official journal of the Japanese Urological Association (2022)
Ryo Sato, Teruo Inamoto, Yuto Matsushita, Ayana Takemura, Taizo Uchimoto, Asuka Sano, Hiroki Tanaka, Gaku Ishikawa, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Takayuki Sugiyama, Atsushi Otsuka, Ken-Ichi Harada, Haruhito Azuma, Hideaki Miyake
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab. International journal of urology : official journal of the Japanese Urological Association (2022)
Ken-Ichi Harada, Hideaki Miyake, Junya Furukawa, Naohiro Fujimoto, Masato Fujisawa
Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association 29 (8) (2022)
Hideto Ueki, Takuto Hara, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study. Investigative and clinical urology 63 (4) (2022)